Apr 30, 2025 14:17 JST

Source: Eisai

Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star

TOKYO, Apr 30, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations. The Order of the Rising Sun, Gold and Silver Star is awarded to individuals who have made distinguished contributions to Japan or the Japanese public in various areas of society. The conferral ceremony will take place at the Imperial Palace on May 9, 2025.

As the Representative Corporate Officer and CEO of Eisai, Haruo Naito has been promoting patient-centric management based on the human health care Concept (hhc Concept) for many years. As a result, he has contributed to fulfilling global healthcare needs through the development of innovative new drugs, including Alzheimer's disease and anti-cancer treatments, as well as continued efforts in global health, such as addressing neglected tropical diseases. He has also been recognized for leading discussions on various institutional reforms, including the drug pricing system and R&D tax system, on behalf of industry associations such as the Japan Pharmaceutical Manufacturers Association, contributing to the improvement of public health quality and the healthy development of the industry.

Comment from Haruo Naito on Receiving the Decoration

I am deeply honored to have been awarded the Order of the Rising Sun, Gold and Silver Star. Since assuming the position of Representative Director and President of Eisai Co., Ltd. in 1988, I have established that patients are the main figures in healthcare. By having our employees spend time with the patients to understand their anxieties, and driven by a strong desire to relieve them somehow, we have been promoting the creation of innovations to meet unmet needs, particularly in the dementia and oncology areas.

With a strong belief in delivering these new treatments to patients who need them regardless of the healthcare system or income level of each country, I have worked to improve access to medicines in countries including developing and emerging nations. Through the activities of industry associations, I have also been committed to the development of the pharmaceutical industry, whose mission is to protect the lives and health of the public.

With this honor, I intend to strive even harder to fulfill my mission of increasing satisfaction for patients in Japan and around the world, contributing to health and welfare, and working towards relieving anxiety over health and reducing health disparities.

Biography of Haruo Naito

Born on December 27, 1947
Mar. 1972 - Graduated from Keio University Faculty of Business and Commerce
Jun. 1974 - Received MBA from Northwestern University Kellogg School of Management Oct. 1975 - Joined Eisai
Apr. 1983 - Senior Director, R&D Promotion Department, Eisai Jun. 1983 - Director, Eisai
Apr. 1985 - General Manager, R&D, Eisai Jun. 1985 - Managing Director, Eisai
Jun. 1986 - Representative Director and Senior Managing Director, Eisai Jun. 1987 - Representative Director and Deputy President, Eisai
Apr. 1988 - Representative Director and President, Eisai
Jun. 2003 - Representative Director, President and Chief Executive Officer (CEO), Eisai Jun. 2004 - Director, President (Representative Corporate Officer) and CEO, Eisai
Jan. 2006 - Chair, The Naito Foundation (current)
Jun. 2014 - Director, Representative Corporate Officer and CEO, Eisai (current)

Industry Association History

May 1998 - Vice President, Japan Pharmaceutical Manufacturers Association
May 1998 - Vice President, Federation of Pharmaceutical Manufacturers' Associations of Japan May 1998 - President, Pharmaceutical Manufacturers’ Association of Tokyo
Nov. 2009 - President, International Federation of Pharmaceutical Manufacturers & Associations May 2012 - President, Federation of Pharmaceutical Manufacturers' Associations of Japan
May 2016 - Vice President, Federation of Pharmaceutical Manufacturers' Associations of Japan May 2016 - Chairman, Pharmaceutical Manufacturers’ Association of Tokyo

Major Honors Received

Apr. 1999 - Awarded Honorary Commander of the Order of the British Empire (CBE) by the United Kingdom
Jun. 2014 - Awarded Knight Commander of the Order of the British Empire (KBE) by the United Kingdom

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
 
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
 
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
 
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
 
More Press release >>

Latest Press Release


More Latest Release >>